CA2929858C - Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis - Google Patents

Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis Download PDF

Info

Publication number
CA2929858C
CA2929858C CA2929858A CA2929858A CA2929858C CA 2929858 C CA2929858 C CA 2929858C CA 2929858 A CA2929858 A CA 2929858A CA 2929858 A CA2929858 A CA 2929858A CA 2929858 C CA2929858 C CA 2929858C
Authority
CA
Canada
Prior art keywords
gastrin
bone
receptor
ovx
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2929858A
Other languages
English (en)
French (fr)
Other versions
CA2929858A1 (en
Inventor
Irvin Mark MODLIN
Mark Kidd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CL Biosciences LLC
Original Assignee
CL Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52118000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2929858(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CL Biosciences LLC filed Critical CL Biosciences LLC
Publication of CA2929858A1 publication Critical patent/CA2929858A1/en
Application granted granted Critical
Publication of CA2929858C publication Critical patent/CA2929858C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2929858A 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis Active CA2929858C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907980P 2013-11-22 2013-11-22
US61/907,980 2013-11-22
PCT/US2014/066832 WO2015077572A1 (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis

Publications (2)

Publication Number Publication Date
CA2929858A1 CA2929858A1 (en) 2015-05-28
CA2929858C true CA2929858C (en) 2022-03-29

Family

ID=52118000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929858A Active CA2929858C (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis

Country Status (14)

Country Link
US (1) US10709714B2 (2)
EP (1) EP3071206B1 (2)
JP (1) JP6502939B2 (2)
KR (1) KR102254957B1 (2)
CN (1) CN106163527A (2)
AU (1) AU2014352875B2 (2)
BR (1) BR112016011727A2 (2)
CA (1) CA2929858C (2)
DK (1) DK3071206T3 (2)
ES (1) ES2870538T3 (2)
MX (1) MX2016006657A (2)
PL (1) PL3071206T3 (2)
RU (1) RU2693484C1 (2)
WO (1) WO2015077572A1 (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881667B2 (en) 2018-10-30 2021-01-05 City University Of Hong Kong Method and composition for treating epilepsy
US11285161B2 (en) 2019-04-26 2022-03-29 City University Of Hong Kong Method and composition for treating mental disorder and pain associated with nerve damage
CN110935005A (zh) * 2019-11-19 2020-03-31 宁波大学 一种丙谷二肽的新用途
CN115770266B (zh) * 2023-01-30 2023-05-09 云南中医药大学 一种用于治疗绝经后骨质疏松的药物组合物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005812A1 (fr) * 1987-12-22 1989-06-29 Yoshitomi Pharmaceutical Industries, Ltd. Composes de thienodiazepine et leur utilisation en medecine
JPH0374328A (ja) 1989-08-04 1991-03-28 Warner Lambert Co 薬学的活性を有する中枢コレシストキニン拮抗剤
US5399565A (en) 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
FI932928A0 (fi) 1990-12-25 1993-06-24 Yamanouchi Pharma Co Ltd Nya bensodiazepinderivat
CA2110986A1 (en) 1991-07-12 1993-01-21 Geoffrey Neil Woodruff Cholecystokinin antagonists useful in the treatment of panic attacks
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
WO1993012817A1 (en) * 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
IL104853A (en) 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
MY128102A (en) 1993-02-17 2007-01-31 Chugai Pharmaceutical Co Ltd Indolin-2-one-derivatives
GB2282595A (en) 1993-08-25 1995-04-12 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
IT1261255B (it) 1993-09-09 1996-05-09 Rotta Research Lab Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
IL124808A0 (en) 1995-12-11 1999-01-26 New England Medical Center Inc Assay for and uses of peptide hormone receptor ligands
US5922883A (en) 1996-04-03 1999-07-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US20040001842A1 (en) 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
ES2227833T3 (es) 1997-05-12 2005-04-01 Aphton Corporation Composiciones inmunogenicas para el receptor cck-b/gastrina y metodos para el tratamiento de tumores.
KR100699574B1 (ko) 1998-05-15 2007-03-23 리셉터 바이오로직스 인크 종양 치료를 위한 조합 치료
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO2000044722A1 (en) 1999-01-29 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US20030191279A1 (en) 1999-08-27 2003-10-09 Goldstein Steven Wayne Urea derivatives useful as anticancer agents
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
DE60026348T2 (de) 1999-11-05 2006-10-19 Societe De Conseils De Recherches Et D`Applications Scientifiques (S.C.R.A.S.) Heterocyclische verbindungen und ihre verwendung als medikamente
AU3003701A (en) 1999-11-19 2001-05-30 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
WO2001077685A2 (en) 2000-04-10 2001-10-18 The General Hospital Corporation Diagnosis and treatment of gastrointestinal disease
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
JP2005508838A (ja) 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
WO2002092096A1 (en) 2001-05-11 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Antitumor agents
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
BR0213317A (pt) 2001-11-13 2004-10-13 Black James Foundation Uso de um composto, método de tratar um distúrbio relacionado com gastrina, composição farmacêutica, kit, usos de uma composição, e de um inibidor de bomba de próton, métodos de preparar uma composição farmacêutica e um composto, e, composto
US20040127492A1 (en) 2002-02-19 2004-07-01 Pharmacia Corporation Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2
DE10207037A1 (de) 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US20030049698A1 (en) 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
KR20050119666A (ko) 2003-03-28 2005-12-21 얀센 파마슈티카 엔.브이. 벤조[1,2,5]티아디아졸 화합물
WO2004101533A1 (en) 2003-05-12 2004-11-25 Janssen Pharmaceutica, N.V. 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands
GB0310865D0 (en) 2003-05-12 2003-06-18 Black James Foundation Gastrin and cholecystokinin receptor ligands
WO2005007107A2 (en) 2003-07-11 2005-01-27 University Of Massachusetts Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
SI1651621T1 (sl) 2003-08-08 2008-12-31 Janssen Pharmaceutica Nv 2-(kinoksalin-5-ilsulfonilamino)-benzamidne spojine kot modulatorji CCK2
US20070293482A1 (en) 2004-03-19 2007-12-20 Novartis Pharmaceuticals Corporation Process for Preparing Benzodiazepines
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7947833B2 (en) 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
CA2581426A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
WO2006044352A2 (en) 2004-10-12 2006-04-27 Janssen Pharmaceutica N.V. Canine cholecystokinin 1 receptor materials and their use
AU2005302669A1 (en) 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as CB1 antagonists
CA2579227A1 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
GB0425196D0 (en) 2004-11-15 2004-12-15 Black James Foundation Gastrin and cholecystokinin receptor ligands
US20090291977A1 (en) 2004-12-17 2009-11-26 Madoka Jinno Chromane Derivatives Useful As Acid Pump Antagonists
DE602006013094D1 (de) 2005-01-19 2010-05-06 Zeria Pharm Co Ltd Krebsmittel
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AU2006255047B2 (en) 2005-06-06 2011-09-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating sleep disorders
DE602006009105D1 (de) 2005-06-14 2009-10-22 Raqualia Pharma Inc Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
ES2324354T3 (es) 2005-07-29 2009-08-05 Rottapharm S.P.A. Combinacion terapeutica de itriglumida e inhibidores de la bomba de protones en el tratamiento de trastornos gastrointestinales y relacionados.
WO2007026218A2 (en) 2005-09-01 2007-03-08 Pfizer Japan Inc. Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists
WO2007031860A1 (en) 2005-09-15 2007-03-22 Pfizer Japan Inc. Indane substituted benzimidazoles and their use as acid pump inhibitors
WO2007072142A2 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Benzimidazole-5-carboxamide derivatives
DE602006014996D1 (de) 2005-12-19 2010-07-29 Raqualia Pharma Inc Chromansubstituierte benzimidazole und ihre verwendung als säurepumpenhemmer
JP2009530262A (ja) 2006-03-17 2009-08-27 ラクオリア創薬株式会社 クロマン誘導体
JP2009533362A (ja) 2006-04-12 2009-09-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キナーゼ媒介性疾患を治療するための複素環式置換ビスアリール尿素のｎ−オキシド
FR2901473B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide
FR2901472B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants
ATE512969T1 (de) 2006-09-21 2011-07-15 Raqualia Pharma Inc Benzimidazolderivate als selektive säurepumpenhemmer
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
WO2008059373A1 (en) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
WO2008114123A1 (en) 2007-03-21 2008-09-25 Raqualia Pharma Inc. Spiro benzimidazole derivatives as acid pump inhibitors
WO2008124518A1 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
WO2008124524A2 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
RU2379043C2 (ru) 2007-08-02 2010-01-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы
US20110105515A1 (en) 2007-08-07 2011-05-05 President And Fellows Of Harvard College Targeting the oncoprotein nucleophosmin
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
JPWO2010113458A1 (ja) 2009-03-31 2012-10-04 ゼリア新薬工業株式会社 １，５−ベンゾジアゼピン誘導体の製造法
EP2452680B1 (en) 2009-07-09 2019-12-18 RaQualia Pharma Inc. Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
EP2480549B1 (en) 2009-09-24 2015-04-08 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Fused imidazo[3,2-d]pyrazines as PI3 kinase inhibitors
HRP20160967T1 (hr) 2009-10-06 2016-10-07 Millennium Pharmaceuticals, Inc. Heterociklički spojevi korisni kao pdk1 inhibitori
US9181414B2 (en) 2009-11-13 2015-11-10 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
WO2011063164A2 (en) 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
CA2812043A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Pyrimidinedione anti-viral compounds
WO2012021837A2 (en) 2010-08-12 2012-02-16 Senomyx, Inc. Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
WO2012068516A2 (en) 2010-11-18 2012-05-24 Pier Pharmaceuticals Low dose cannabinoid medicaments
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
ES2736603T3 (es) 2011-11-07 2020-01-03 Massachusetts Inst Technology Complejos de wolframio oxo alquilideno para la metátesis de olefinas selectiva de Z
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors

Also Published As

Publication number Publication date
BR112016011727A2 (pt) 2017-08-08
JP2016538295A (ja) 2016-12-08
EP3071206A1 (en) 2016-09-28
RU2016124538A (ru) 2017-12-27
CA2929858A1 (en) 2015-05-28
KR102254957B1 (ko) 2021-05-25
WO2015077572A1 (en) 2015-05-28
JP6502939B2 (ja) 2019-04-17
EP3071206B1 (en) 2021-02-17
US20150148339A1 (en) 2015-05-28
RU2693484C1 (ru) 2019-07-03
DK3071206T3 (da) 2021-05-25
AU2014352875A8 (en) 2016-06-30
US10709714B2 (en) 2020-07-14
PL3071206T3 (pl) 2022-01-17
AU2014352875A1 (en) 2016-05-26
ES2870538T3 (es) 2021-10-27
KR20160088891A (ko) 2016-07-26
CN106163527A (zh) 2016-11-23
AU2014352875B2 (en) 2019-10-24
MX2016006657A (es) 2016-10-12

Similar Documents

Publication Publication Date Title
Tabatabaei-Malazy et al. New horizons in treatment of osteoporosis
D’Oronzo et al. Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications
Kim et al. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss
Pitts et al. Update on medications with adverse skeletal effects
US7576053B2 (en) Methods and compositions for treating degenerative bone disorders
China et al. Globular adiponectin reverses osteo-sarcopenia and altered body composition in ovariectomized rats
Billert et al. Phoenixin-14 stimulates differentiation of 3T3-L1 preadipocytes via cAMP/Epac-dependent mechanism
Salari Sharif et al. Current, new and future treatments of osteoporosis
Israeli et al. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy
Tando et al. Hif1α is required for osteoclast activation and bone loss in male osteoporosis
CA2929858C (en) Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
Thomas Intermittent parathyroid hormone therapy to increase bone formation
Wang et al. The systemic bone protective effects of Gushukang granules in ovariectomized mice by inhibiting osteoclastogenesis and stimulating osteoblastogenesis
Wei et al. Effect of whole body vibration therapy on circulating serotonin levels in an ovariectomized rat model of osteoporosis
Journé et al. Extracellular calcium downregulates estrogen receptor alpha and increases its transcriptional activity through calcium-sensing receptor in breast cancer cells
Mohanty et al. Molecular mechanisms and treatment strategies for estrogen deficiency-related and glucocorticoid-induced osteoporosis: a comprehensive review: S. Mohanty et al.
Neuprez et al. Bone-forming agents in the management of osteoporosis
Abo-Elenin et al. An overview of osteoporosis and possible treatment approaches
Appelman-Dijkstra et al. Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches
Li et al. Functional interactions between calmodulin and estrogen receptor-α
HK1230487A1 (en) Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
Abo-Rayah et al. Forskolin Could Protect Against Flutamide-Induced Osteoporosis By Modulation of Serum Osteocalcin and Sclerostin In Rats
Di Bari et al. Vitamin D, bone metabolism, and fracture risk in polycystic ovary syndrome Metabolites. 2021; 11: 116
Fasipe et al. Osteoporosis Now and in the Future: The Role of Newer Emerging Agents in the Management of Osteoporotic Bone Diseases–A Review
Cardinali et al. Melatonin Use as a Bone-Protecting Substance

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191115

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241115

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241115

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251105